13 results about "Diabetic rat" patented technology

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The present application relates to a kind of porous scaffold for repairing bone defect loaded with black phosphorus active oxygen elimination and slow-release drug and its preparation method;The scaffold includes the amino cation polymer grafted with the phenylboronic acid (PBA) and cyclodextrin (CD) that can eliminate active oxygen, black phosphorus nanosheet (BP) and scaffold material poly (lactic acid-glycolic acid) (PLGA).The porous scaffold loads a large number of black phosphorus nanosheet that can be hydrolyzed into bone repair nutrients, and the porous structure provides sufficient space for cell migration and growth, realizes the good repair of bone.Active oxygen elimination ability, can eliminate active oxygen in diabetic microenvironment.In addition, cyclodextrin can load a variety of drugs, such as osteogenic differentiation induction drug, and realize the slow release of drug.The porous scaffold has good biocompatibility, and the degradation product is harmless to human body, can be used for the tissue repair of bone defect, can be widely applied in the field of biological medicine and tissue engineering, and has been proved to have good repair ability in the diabetic rat skull defect model.

The invention discloses eye drops for treating vascular hyperplasia of eyes and a preparation method of the eye drops, and belongs to the technical field of biological pharmacy. The eye drops comprise a recombinant human angiostatin protein, an endostatin protein and a pharmaceutically acceptable carrier, wherein the recombinant human angiostatin protein and the endostatin protein are used for preparing the eye drops. Experiments show that the eye drops show remarkable vascular inhibition activity in a chick embryo chorioallantoic membrane model and a diabetic rat retina hyperplasia model, and the two proteins are combined for use to achieve a synergistic effect; the invention provides a safe and effective new way for local treatment of ocular vascular hyperplasia diseases.

The application belongs to the field of biomedical materials, and discloses a multifunctional hydrogel suitable for diabetic wound healing. The hydrogel is compounded by HA-Tris, EPL-Cpb and MXene / Mn composite nanoparticles in a mass ratio of 2:1:(0-0.2), and is rapidly crosslinked in 1 min through a triple mechanism, with a crosslinking efficiency increased by more than 80% compared with traditional methods and a yield of more than 99.5%. The application realizes chemical-photothermal dual-mode antibiosis through precise optimization of the ratio and reaction conditions and the function synergy of the components, with an inhibition rate of 96.86% and 97.23% for Escherichia coli and Staphylococcus aureus, which is increased by more than 62% compared with traditional silver-containing dressings; the hydrogel has a ROS clearance rate of 92.5% and an in-situ oxygen production rate increased by 58% compared with traditional methods, and can efficiently stop bleeding within 30 s, with a blood loss reduced by 90.3% compared with the blank group. The hydrogel has excellent biocompatibility and can comprehensively improve the pathological microenvironment of diabetic wounds, shortening the healing period of full-thickness skin wounds of diabetic rats from 21 days to 10 days, and providing a new and efficient biomedical material for the treatment of diabetic wounds.

The invention relates to application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes, and belongs to the technical field of photomedicine. The invention provides application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes. According to the invention, a diabetic rat model is established, near-infrared light and blue light are adopted to carry out phototherapy on diabetic rats, and blood sugar and blood fat related indexes of the diabetic rats and changes of different tissue forms and behaviors of the rats are measured; results show that the near-infrared light and the blue light can effectively improve blood sugar and blood fat related indexes of the rats after phototherapy of the rats, and can also improve tissue morphology and cognitive behaviors of the diabetic rats, which indicates that the phototherapy of the near-infrared light or the blue light has the effects of treating diabetic blood sugar and cognition, can reduce dependence of patients on medicines, and can improve the curative effect of the patients on diabetes mellitus. And new experimental basis and theoretical support are provided for clinical non-drug intervention of diabetes.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

The invention provides a preparation method of medical titanium of a silicon dioxide and Prussian blue nano-particle composite coating with multiple biological functions and a medical titanium product obtained by the method aiming at the defects that an existing titanium implant surface modification technology is single in function and difficult to adapt to a complex pathological environment. The invention also discloses application of the medical titanium product in a diabetic rat maxilla implantation experiment.

This invention provides the application of transcription factor CUX1 in the preparation of products for the prevention and treatment of diabetic foot ulcers, belonging to the field of biomedical technology. Its key technical point lies in providing the application of transcription factor CUX1 as a target in the preparation of products for the prevention and treatment of diabetic foot ulcers. This application confirms the high expression of transcription factor CUX1 in diabetic foot ulcer wound tissue through specific verification experiments. Using a diabetic rat model of ischemic foot ulcers in the lower limbs, this invention is the first to clearly demonstrate a significant increase in the expression of transcription factor CUX1 in diabetic ulcer wound tissue. Using a high-glucose, high-lipid cell injury model, it is the first to demonstrate that CUX1 expression is significantly high after fibroblast injury due to high glucose and high lipid levels. It is the first to discover that transcription factors have a protective effect on fibroblasts injured by high glucose and high lipid levels. This invention provides a new approach for the treatment of diabetic foot ulcers and a new target for the development of diabetic wound healing.

The application discloses a new application of mulberry polysaccharide in preparation of a medicine for treating type 2 diabetes by regulating intestinal flora, and belongs to the technical field of medicinal and edible plant polysaccharides. In the application, a type 2 diabetes rat model is constructed by using high-sugar and high-fat feed in combination with streptozotocin, biochemical index detection, liver HE staining and oil red O staining, intestinal flora 16S rRNA high-throughput sequencing, and GC-MS detection of short-chain fatty acid content are carried out, so as to confirm that the mulberry polysaccharide can regulate the intestinal flora structure of T2DM rats, improve the secretion level of short-chain fatty acids, improve insulin resistance and glycolipid metabolism disorder, enhance the antioxidant capacity of the body, and repair the pathological damage of the liver. The application clearly defines the anti-type 2 diabetes mechanism of the mulberry polysaccharide, which takes the intestinal flora-short-chain fatty acid axis as the core. The mulberry polysaccharide is a natural low-toxicity medicinal and edible active ingredient, has no side effects of chemical hypoglycemic drugs, can be prepared into various oral medicine dosage forms, and is used for the prevention and clinical treatment of type 2 diabetes, so the application prospect is wide.

A compound represented by formula (I) and a preparation method thereof, and a pharmaceutically acceptable salt thereof, a metabolic precursor thereof, a metabolite thereof, an isomer thereof or a prodrug thereof; experiments show that the indole alkaloid not only promotes axon growth of peripheral sensory neurons, improves the nerve conduction velocity and anesthesia symptom of diabetic rats, but also promotes healing of foot ulcer wounds of diabetic rats, thus having good therapeutic effects on diabetic complication peripheral neuropathy and diabetic feet; they also show that the indole alkaloid also obviously reduces a degree of pulmonary fibrosis induced by bleomycin in mice, and plays a role in protecting lung tissues.

This invention relates to the field of biomedical technology, and particularly to a method and application for identifying active ingredients for the prevention and treatment of diabetes from non-medicinal Astragalus membranaceus slices. The method includes: first, qualitative and quantitative analysis of the chemical components of Astragalus membranaceus and longan slices; second, evaluation of its hypoglycemic efficacy using a diabetic rat model to verify the effects of Astragalus membranaceus and longan slices in lowering blood sugar, improving insulin resistance, and reducing inflammation; and finally, integration of non-targeted and pseudo-targeted metabolomics technologies to systematically identify the core active ingredients in key pathways for the prevention and treatment of diabetes by analyzing the correlation between chemical components and efficacy indicators. This invention not only reveals the main pharmacodynamic substances of Astragalus membranaceus in the prevention and treatment of diabetes, but also provides a theoretical basis and technical support for the development of related functional products or innovative drugs, and for comprehensively improving the utilization efficiency and economic value of Astragalus membranaceus resources.

The invention relates to the technical field of biological medicine, in particular to application of troxerutin in preparation of a medicine for improving dyslipidemia. According to the application disclosed by the invention, in a streptozotocin-induced type 2 diabetes rat model, the intervention of troxerutin for seven weeks generates a remarkable and dose-dependent improvement effect, and the effect of troxerutin reaches a level which can be compared with or even better than that of a reference drug metformin (10 mg / kg / day). And the troxerutin is derived from a natural plant, the water-soluble characteristic of the troxerutin is beneficial to absorption and metabolism, and no obvious adverse reaction is observed in the experimental period of the invention, which indicates that the troxerutin has better safety than many synthetic drugs.

The application discloses a kind of stem cell exosome based on targeted fusion polypeptide modification, preparation method and its application in treating male erectile dysfunction.The exosome is anchored on the surface by chemical coupling technology with specific targeted fusion polypeptide (sequence: EPLQLKM-GGGGS-DPPV), which enhances its targeting to cavernosal smooth muscle cells;At the same time, by loading anti-TrkA monoclonal antibody (TrkA-2E7-HL) through electroporation method, the fibrosis pathway mediated by nerve growth factor (NGF) is inhibited.The exosome is induced by antioxidant culture medium to induce umbilical cord mesenchymal stem cells to secrete, which significantly improves its antioxidant activity.Experiments show that the erectile function (ICP / MAP ratio) of the exosome after modification is increased to 0.79±0.05 in a diabetic ED rat model, the fibrosis area is reduced to 9.2±1.6%, and the NO secretion level is increased by 3.5 times compared with ordinary exosome.The application realizes effective reversal of ED pathological process through polypeptide targeting, antibody synergy and antioxidant triple mechanism, and has significant novelty and clinical transformation potential.